logo

JAZZ

Jazz Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
6.50 / 10
Outperform

Analyst consensus is overwhelmingly bullish with a Strong Buy rating from two analysts, supported by a 5.22 historical weighted rating. Fund flow evaluation is strong (7.78/10), with positive trends in block, small, and extra-large inflows, although medium and large inflows are negative. The sentiment score of 6.5 indicates an Outperform stance, reflecting robust fund flow characteristics and a positive analyst outlook.

FundamentalSentiment(6.5)Technical
Fund Flow Rating
Analyst RatingStrong Buy

Wall Street Opinions

Strong Buy

Strong Buy

100%

Buy

0%

Hold

0%

Sell

0%

Strong Sell

0%

Date2026-01-12
InstitutionNeedham
Times predicted9
Historical Win Rate55.6%
What is the analyst consensus for JAZZ?
  • JAZZ holds a Bullish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.50/10 (Outperform).